1. Introduction {#s0005}
===============

*Staphylococcus aureus* (*S. aureus*) causes a number of opportunistic infections that range from relatively benign skin infections to life-threatening diseases including endocarditis, pneumonia and sepsis ([@bb0110], [@bb0125]). Clumping factor A (ClfA) is a fibrinogen (Fg) binding microbial surface component recognizing adhesive matrix molecules (MSCRAMM), and an important virulence factor of *S. aureus.* ClfA plays a role in the molecular pathogenesis of several types of experimental infections such as septic arthritis, infective endocarditis, kidney abscesses and sepsis/septicemia ([@bb0035], [@bb0095], [@bb0130], [@bb0175]). Furthermore ClfA is important for *S. aureus* colonization of biomaterials, which presumably becomes coated with plasma proteins such as Fg once implanted ([@bb0190]). ClfA binds to the carboxy terminal of the γ-chain of Fg ([@bb0135], [@bb0140]), a region that is important for platelet aggregation and coagulation ([@bb0080], [@bb0090], [@bb0105]) and recombinant ClfA has been reported to inhibit the interaction of Fg with the platelet integrin α~IIb~β~3~ ([@bb0120], [@bb0115]). However, the virulence potential of ClfA in a mouse model of septicemia does not appear to correlate with altered platelet aggregation or Fg coagulation but rather seems to be a function of impaired bacterial clearance ([@bb0035]). In fact ClfA can protect *S. aureus* against phagocytosis by macrophages ([@bb0160]) and it appears that Fg binding to the MSCRAMM is required for the ClfA mediated inhibition of phagocytosis ([@bb0085]). In addition, ClfA has been reported to bind complement factor I. This interaction may also play a role in ClfA dependent resistance to bacterial clearance ([@bb0065], [@bb0060]).

Due to the importance of ClfA as a virulence factor, the protein has been explored as a potential vaccine candidate. Recombinant ClfA induced an antibody response in mice ([@bb0100]) and mice immunized with ClfA presented with less severe arthritis compared to mice immunized with a control antigen ([@bb0095]). Moreover, passive immunization with polyclonal ClfA antibodies generated in rats or rabbits protected mice against *S. aureus* induced sepsis and arthritis ([@bb0095]). Recently, a multi-mechanistic mAb targeting ClfA and the Alpha toxin was shown to be protective against *S. aureus* infection in a mouse model ([@bb0185]). A combination therapy of vancomycin with high titers of human polyclonal Abs or a mouse monoclonal antibody (mAb) called aurexis or 12-9 against ClfA was effective in a catheter induced infective endocarditis model in rabbits where treating with vancomycin alone was less effective ([@bb0165], [@bb0195], [@bb0205]). However, when tefibazumab, a humanized version of aurexis, was used together with antibiotics in a limited phase II clinical trial the results were less impressive ([@bb0165], [@bb0205]).

The domain organization of ClfA is prototypic for the MSCRAMM subfamily of cell wall anchored staphylococcal proteins ([@bb0045]). The N-terminus contains a signal sequence followed by the ligand-binding A region that is composed of three subdomains N1, N2 and N3. C-terminal of the A region is the serine-aspartate repeat (Sdr) domain which can become glycosylated ([@bb0180], [@bb0075]) followed by the LPXTG motif and other features required for cell wall anchoring. A segment composed of subdomains N2 and N3 binds a peptide mimicking the C-terminus of Fg γ-chain (γ-peptide) ([@bb0140]) and a segment containing amino acids 229--545 of ClfA (ClfA~229--545~) was shown to represent the minimal protein necessary for appreciable Fg binding ([@bb0050]).

Many of the staphylococcal MSCRAMMs appear to bind their ligands by variations of the Dock, Lock and Latch (DLL) binding mechanism (for a recent review see [@bb0045]). This dynamic binding mechanism was first proposed after analyzing crystal structures of both the apo (open) and the ligand-bound (closed) forms of the N2N3 ligand-binding segment of the *Staphylococcus epidermidis* Fg-binding MSCRAMM SdrG ([@bb0170]). Subsequent biochemical studies confirmed the major steps of the DLL mechanism for SdrG ([@bb0010]). ClfA~D327C/K541C~ (ClfA~CC~) is a variant of ClfA that has a double amino acid substitution to lock ClfA in the closed conformation through formation of a disulfide bridge ([@bb0050]). While the corresponding SdrG~CC~ is unable to bind ligand due to the closure of the docking trench, ClfA~CC~ surprisingly exhibits a higher affinity for the Fg γ-peptide than the wild-type ClfA~229--545~ ([@bb0050]). Subsequent structural and biochemical characterization revealed that ClfA binds to Fg by a variant of the DLL mechanism where locking and latching can precede ligand docking ([@bb0050]).

In order to understand the detailed mechanism of action of tefibazumab, we used a combination of structural, biochemical and biophysical approaches to gain insight into the molecular details of the mAb\'s interaction with ClfA and the effects on the MSCRAMM\'s Fg binding. We determined the crystal structure of ClfA~CC~ in complex with a Fab fragment of tefibazumab. In the co-crystal structure, tefibazumab is bound to the "top" of the N3 domain of ClfA. This mAb binding site is distinct from the trench between N2 and N3 subdomains where the Fg γ-peptide docks ([@bb0050]) and suggests that residues outside the docking trench on ClfA are also important for Fg binding. Further biochemical studies demonstrate the presence of a second Fg binding site on top of N3 that is critical for an overall high affinity Fg/ClfA interaction. These results reveal that tefibazumab inhibits ClfA binding to Fg by targeting a previously unknown Fg binding site on the MSCRAMM and provide additional target sites for future design of effective inhibitors of the ClfA/Fg interaction.

2. Materials and Methods {#s0010}
========================

2.1. Bacterial Strains, Plasmids and Primers {#s0015}
--------------------------------------------

Amino acid substitutions in the tefibazumab epitope of ClfA were generated in the plasmid pQE30 vector expressing ClfA~229--545~ from *S. aureus* strain Newman ([@bb0050]) by site-directed mutagenesis using the primers listed in Supplementary Table ST6. Plasmid pCF41 ([@bb0150]) carrying DNA encoding ClfA~221--559~ served as template for introducing Y~512~A, P~467~A and W~518~A substitutions. Overlapping complementary primers containing the desired nucleotide changes (Supplementary Table ST6) were used to amplify the plasmid.

The PCR reaction was incubated with 1 U of the restriction enzyme *Dpn*I (New England Biolabs) for 1 h at 37 °C to digest methylated DNA used as template and transformed into *E. coli* TG1 (Zymo Research). *E. coli* was grown at 37 °C in Luria-Bertani (LB) broth supplemented with ampicillin (100 μg/ml, Sigma-Aldrich). Plasmids were extracted with Wizard Plus SV Minipreps DNA purification system (Promega) and the mutation was confirmed by DNA sequencing (Genewiz).

2.2. Recombinant Proteins {#s0020}
-------------------------

The recombinant proteins were expressed in *E. coli* Topp3 (Bayou Biolabs) and purified by nickel chelate chromatography and anion exchange chromatography as previously described ([@bb0200]). The GST tagged γ-peptide was expressed and purified as described earlier ([@bb0150]). Proteins and peptide used in this study and their specific names are listed in Supplementary Table ST1.

2.3. Fibrinogen {#s0025}
---------------

Human fibrinogen (Catalog \# FIB3, Enzyme Research Laboratories, South Bend, IN) was used in all experiments and dialysed against 150 mM NaCl; 10 mM KCl; 25 mM Tris pH 7.4 (TBS buffer) unless prepared as described. Fibrinogen D-fragment was purchased from Millipore (Calbiochem, catalog \#341600).

2.4. Generation of Fab Fragments {#s0030}
--------------------------------

Purified tefibazumab (a generous gift of Inhibitex, Inc.) was dialyzed against 20 mM sodium phosphate pH 7.0 and adjusted to a final concentration of \~ 10 mg/ml. Beads containing immobilized papain (Thermo Scientific, Rockford, IL) were washed 3 times with phosphate buffer and a 50% slurry was made with the digestion buffer, 20 mM phosphate, 20 mM cysteine, 10 mM EDTA, pH 7.0. Five hundred μl of slurry was added to 2 ml sample supplemented with 20 mM of cysteine and the mixture was incubated for 8 h at 37 °C. The papain beads were then removed by centrifugation and the digest was dialyzed against phosphate buffer. Subsequently undigested IgG and generated Fc fragments were removed by passing the mixture through a protein A column (Thermo Scientific, Rockford, IL).

2.5. Crystallization, Structure Solution and Refinement {#s0035}
-------------------------------------------------------

The isolated Fab fragments were mixed with purified ClfA~CC~ at an equal molar ratio and left for 1 h at 4 °C. The complex was then concentrated to \~ 10 mg/ml for crystallization experiments. Two microliters of the sample was mixed with 2 μl of reservoir solution containing PEG 4000, 2% isopropanol, 0.1 M Hepes pH 7.0 and allowed to equilibrate in a linbro plate at 4 °C. Several crystals were collected, washed 3 times with stabilizing solution, then dissolved and run on an SDS-page gel to confirm the presence of both proteins. The X-ray diffraction data was collected at Advanced Photon Source at Argonne National laboratory for 210° with an oscillation width of 1°. Data was processed using HKL2000 ([@bb0155]). The structure was solved by the molecular replacement (MR) method using ClfA~CC~ (pdbid; [1VR3](pdb:1VR3){#ir0015}) as the search model. To determine the MR solution for the Fab fragment, several poly-alanine models of Fv fragments from the PDB database were attempted of which pdb id; [1F8T](pdb:1F8T){#ir0020} ([@bb0040]) yielded a reasonable MR solution. The model was rebuilt using Coot ([@bb0030]) and refined using PHENIX ([@bb0005]) and Refmac 5.0 ([@bb0145]) to a final R-factor of 0.207 and an R free of 0.259. Several regions in the constant domain of the mAb showed poor density and therefore backbone atoms were modeled wherever possible. The data collection and refinement statistics are summarized in [Table 1](#t0005){ref-type="table"}.

2.6. Isothermal Titration Calorimetry {#s0040}
-------------------------------------

Isothermal titration calorimetry (ITC) experiments were carried out using a VP-ITC instrument (MicroCal). In experiments where the interaction of soluble Fg with ClfA~CC~ was characterized the two proteins were co-dialyzed against TBS. The titration was performed at 30 °C using a preliminary injection of 5 μl followed by 29 injections of 10 μl with an injection speed of 0.5 μl/s and a stirring speed of 260 rpm. The cell contained 7 μM Fg (dimer concentration) and the syringe contained 150 μM ClfA~CC~. Since Fg is a dimeric molecule, a single site binding model with 14 μM concentration of Fg was used for data fitting and analyzed using Origin version 5 software (MicroCal).

For ClfA~PWY~/P16 peptide interaction, the protein was dialyzed and the peptide dissolved in the binding buffer and 10 μl aliquots of 0.5 mM P16 peptide were injected into the cell containing 30 μM of ClfA~PWY.~

2.7. Surface Plasmon Resonance {#s0045}
------------------------------

Surface plasmon resonance-based binding experiments were performed at 25 °C on a Biacore 3000 (GE Healthcare/Biacore, Uppsala, Sweden). Phosphate buffered saline (PBS-T: 8.06 mM Na~2~HPO~4~ and 1.94 mM KH~2~PO~4~ (pH 7.4), 2.7 mM KCl, 137 mM NaCl, and 0.005% Tween-20) was used as running buffer for immobilization and binding experiments. A flow rate of 5 μl/min was used during immobilization and a higher rate of 30 or 50 μl/min for binding experiments. The sensor surfaces of Fg, D-fragment or ClfA proteins were prepared on different sensor chips (CM5 for high density, CM3 for medium density and *C*1 for low density ligand surfaces). The ligands were covalently coupled to the chips using standard amine-coupling chemistry. Frozen Fg stock (about 10 mg/ml in 20 mM sodium citrate-HCl, pH 7.4) were thawed in a 37 °C water bath without any agitation. After equilibrating to room temperature, Fg was diluted in 10 mM sodium acetate (pH 5.5) to 10 or 20 μg/ml and injected into an EDC/NHS activated flow cell. The surface was deactivated with ethanolamine. Fg D-fragment (5 μg/ml), ClfA~229--545~ and ClfA~221--559~ (\~ 20 μg/ml) were prepared in 10 mM sodium acetate (pH 5.0), ClfA~CC~ was prepared in 10 mM sodium acetate (pH 4.5) at 40 μg/ml for immobilization. A reference surface was made with activation and deactivation steps but with no protein coupled. To prepare a capturing surface for tefibazumab, about 1400 RU of F(ab')2-goat *anti*-human IgG Fc gamma antibody (Thermo Fisher Scientific Catalog \#31163) were immobilized on CM5 chip using 5 μg/ml of F(ab')~2~ in 10 mM sodium acetate pH 5.5. Tefibazumab was diluted in PBS-T and captured by F(ab')~2~, and another flow cell with only immobilized F(ab')~2~ served as reference surface. For capturing the GST fusion protein, approximately 11,000 RU of goat anti-GST antibody (GE Healthcare/Biacore) was immobilized on a CM5 chip. The GST-tagged Fg γ peptide was captured by the antibody and created a GST-γ ligand surface. Another flow cell with immobilized anti-GST antibody and captured GST was used a reference surface. To regenerate the ligand surfaces, bound proteins were removed by a 1 min injection of 1 M NaCl for the Fg surface, 10 mM glycine pH 2.6 for tefibazumab surface, and 0.01% SDS for the GST-γ surface.

All SPR responses were baseline corrected by subtracting the response generated from the corresponding reference surface. Double-referenced SPR response curves (with the buffer blank run further subtracted) were used for affinity determination. For steady-state interaction, the equilibrium response of each injection was collected and plotted against the concentration of injected protein. A one-site binding (hyperbola) model was fitted to the data (GraphPad Prism 4, GraphPad Software, Inc., La Jolla, CA, USA) to obtain the equilibrium dissociation constant *K*~D~. Non-equilibrium data were globally fitted to a 1:1 Langmuir binding model using BIAevaluation software (Version 4.1). Association and dissociation rate constants *k*~a1~ and *k*~d~ were obtained from the fitting, and the dissociation constant *K*~D~ was derived (*K*~D~ = *k*~d~ / *k*~a~). Errors are reported as standard error of mean from two or more experiments.

3. Results {#s0050}
==========

3.1. Tefibazumab Binds to Different Forms of ClfA and Partially Inhibits the Binding of ClfA to Fibrinogen {#s0055}
----------------------------------------------------------------------------------------------------------

The mAb 12-9 (also called aurexis) was raised in mice using ClfA~221--559~ from *S. aureus* strain Newman as the antigen and was shown via SPR analysis to bind strongly to the A domain ClfA~40--559~ with a reported dissociation constant *K*~D~ of 0.21 nM (rate constants *k*~a~ = 1.99 × 10^6^ M^− 1^ s^− 1^ and *k*~d~ = 4.18 × 10^− 4^ s^− 1^) ([@bb0070]). We recorded very similar binding parameters for 12-9\'s interaction with ClfA~221--559~ with a *K*~D~ of 0.25 nM (rate constants; *k*~a~ = 2.28 × 10^6^ M^− 1^ s^− 1^ and *k*~d~ = 5.71 × 10^− 4^ s^− 1^, Fig. S1A). Earlier structural and biochemical studies showed that two shorter variants of ClfA covering residues 229--545 called ClfA~229--545~ and ClfA~CC~, respectively, also effectively bound to Fg ([@bb0050]). In ClfA~CC~ two Cys residues (D327C/K541C) have been introduced to form a disulfide bond and keep the latch in the latching trench. Since the N2N3 subdomain orientation of ClfA~221--559~ and ClfA~CC~ are different as revealed by the corresponding crystal structures ([@bb0020], [@bb0050]) we compared the binding of tefibazumab (the humanized form of aurexis) to different forms of ClfA N2N3. As shown in Fig. S1B & C, tefibazumab binds to all three forms of ClfA (ClfA~221--559,~ ClfA~229--545~ and ClfA~CC~) in a very similar manner, and it can inhibit the binding of ClfA~229--545~ to Fg or Fg D-fragment.

Using the same SPR technique, we characterized the binding of tefibazumab to ClfA~229--545~ and ClfA~221--559~, (see Supplementary Table ST1 for detailed descriptions of the proteins). The results show that compared to the original mouse mAb 12-9, tefibazumab bound to ClfA~229--545~ with a somewhat weaker affinity; *K*~D~ of 0.79 ± 0.03 nM (*k*~a~ = 5.94 ± 0.26 × 10^5^ M^− 1^ s^− 1^ and *k*~d~ = 4.90 ± 0.14 × 10^− 4^ s^− 1^; [Fig. 1](#f0005){ref-type="fig"}A). The almost four-fold decrease in affinity is mainly due to a slower on-rate, while the off-rate is similar with the two forms of mAb. Furthermore, the data demonstrate that the epitope for tefibazumab is confined within the N2N3 subdomain and is present in all our recombinant forms of this region.

We then examined tefibazumab\'s ability to inhibit ClfA binding to Fg. Even though tefibazumab binds ClfA~229--545~ with \~ 800-fold higher affinity (lower *K*~D~) than Fg (*K*~D~ values of 0.79 ± 0.03 nM vs. 0.61 ± 0.05 μM, [Fig. 1](#f0005){ref-type="fig"}A & B), the mAb\'s ability to inhibit ClfA~229--545~ binding to immobilized Fg is relatively weak, with an IC~50~ of 0.33 ± 0.06 μM ([Fig. 1](#f0005){ref-type="fig"}C & E), only marginally better than that observed for soluble Fg\'s inhibition of ClfA binding to immobilized Fg (IC~50~ = 0.43 ± 0.05 μM, [Fig. 1](#f0005){ref-type="fig"}D & E). Furthermore, while soluble Fg could completely inhibit ClfA~229--545~ binding to immobilized Fg, there was about 25% of the Fg/ClfA~229--545~ interaction that tefibazumab could not block ([Fig. 1](#f0005){ref-type="fig"} C, D & E). These data indicate that tefibazumab binds ClfA strongly but does not efficiently or completely neutralize the Fg binding activity of ClfA.

3.2. Overall Structure of the ClfA/Tefibazumab Fab Complex {#s0060}
----------------------------------------------------------

To uncover the structural basis for the ability of tefibazumab to inhibit ClfA binding to Fg and to determine the epitope on ClfA recognized by the mAb we attempted to crystallize a Fab fragment in complex with ClfA~CC~ (which is more stable than our other recombinant forms of ClfA N2N3). The Fab fragment of tefibazumab was generated by digesting the mAb with immobilized papain and cleared by passing the digest through an immobilized protein A column to remove undigested Abs and Fc containing antibody fragments. Different crystallization screens were initially performed for the MSCRAMM/Fab fragment. The conditions described in [Materials and Methods](#s0010){ref-type="sec"} were used to generate relatively large crystals suitable for X-ray analyses. The crystals diffracted X-rays to a 2.4 Å resolution and the structure of the complex was solved by the molecular replacement method. The data collection and refinement statistics are summarized in [Table 1](#t0005){ref-type="table"}.

The overall structure of the complex is shown in [Fig. 2](#f0010){ref-type="fig"}A. As expected, ClfA~CC~ was found in the latched, closed form due to the presence of the engineered disulfide bond. The overall structure of ClfA in the complex is similar to the structure observed in the ClfA~CC~/Fg γ-peptide complex ([@bb0050]) with an rms deviation of 0.62 Å for 302 Cα atoms.

The tefibazumab Fab binds only to the ClfA N3 domain making it unlikely that the mAb could affect N2-N3 subdomain orientations ([Fig. 2](#f0010){ref-type="fig"}A) consistent with the SPR data showing that Tefibazumab (Fig. S1B) binds equally well to ClfA~221--559~ and ClfA~CC~. Furthermore, the overall structure of the N3 subdomain in the Fab/ClfA~CC~ complex is very similar to the structures of the N3 subdomain in other ClfA structures and show rms deviations of 0.4 Å and 0.3 Å with the apo-ClfA~221--559~ ([@bb0020]) and ClfA~CC~/Fg γ-peptide ([@bb0050]) structures, respectively. Thus the binding of the Fab fragment to ClfA~CC~ does not seem to induce any major conformational change in the MSCRAMM. Furthermore, tefibazumab binds on "top" of the N3 subdomain of ClfA where the mAb would not affect the redirection of the N3 C-terminal extension in ClfA~221--559~ including the locking and latching events. These conclusions are consistent with the experimental data showing that the mAb binds to the closed form of ClfA~CC~. The Fab/MSCRAMM complex in total buries a solvent associable area of 2118 Å^2^ (ClfA: 1007 Å^2^, Fab: 1111 Å^2^) with the heavy chain burying more surface area than the light chain. The residues in the ClfA N3 domain buried by tefibazumab binding are shown in Supplementary Table ST2.

3.3. The Tefibazumab Epitope: The ClfA/Fab Light Chain Interaction {#s0065}
------------------------------------------------------------------

The interaction of ClfA with the light chain of tefibazumab is primarily hydrophilic in nature and is shown in [Fig. 2](#f0010){ref-type="fig"}B. In total nine hydrogen bonds (\< 3.2 Å cut off distance) help stabilize the light chain/ClfA~CC~ interactions ([Fig. 2](#f0010){ref-type="fig"}B). These hydrogen bonds are listed in Supplementary Table ST3. The long CDR1 of the light chain makes extensive contact with ClfA with eight hydrogen bond interactions. Tyr31(OH) (CDR1) is involved in two hydrogen bonds with the backbone atoms of Ile433(N) and Thr431(O) of ClfA. Ser33 (CDR1) interacts with Ile433(O) and Lys434(NZ) while Lys36, and Tyr38 (CDR1) interact with carbonyl oxygens of Asn460 and Thr464 in ClfA, respectively. In addition, Lys434(NZ) and Asn460(OD1) of ClfA contact the backbone atoms of CDR1 residues Ser33(O) and Asn34(O), respectively, through hydrogen bonds. The interaction with CDR3 is less extensive with one backbone-backbone hydrogen bond between Phe466 (ClfA) and Leu98 (CDR3). There is no contact between CDR2 of the light chain and ClfA within 4.0 Å cut-off distance. A list of all residues in ClfA and Tefibazumab Fab making contact (within a 4 Å cut off distance) is presented in Supplementary Table ST4.

3.4. The Tefibazumab Epitope: The ClfA/Fab Heavy Chain Interaction {#s0070}
------------------------------------------------------------------

The interaction between ClfA and the heavy chain of tefibazumab is predominantly hydrophobic in nature with six hydrogen bonds (\< 3.2 Å cut off distance) between the heavy chain and ClfA (Supplementary Table ST3). A view of the ClfA/Fab heavy chain interactions is shown in [Fig. 2](#f0010){ref-type="fig"}C. The side chains of Tyr512 and Asp481 of ClfA form hydrogen bonds with residues in the CDR1 targeting the backbone carbonyl oxygen "O" of Ser30 and the side chain of Arg31(NH1), respectively. The Trp518(NE1) and Asn468(ND2) form hydrogen bonds with the CDR2 residues Asn56(OD1) and Asn468(ND2). In addition, Asn477 and Asn463 participate in hydrogen bonds with the backbone oxygen (O) of Phe101 and Gly104, respectively. Surface exposed Trp518 of ClfA stacks with the backbone of Gly54 of the heavy chain. Trp52 of CDR2 docks in a hydrophobic pocket formed by Val411, Trp518 and Tyr510 of ClfA. In addition, a significant number of hydrophobic residues that are surface exposed in the apo structure of ClfA are masked by the interaction with the Fab. Masking of this large patch of a hydrophobic surface could be responsible for the high affinity that tefibazumab shows for ClfA.

3.5. Biochemical Characterization of the Tefibazumab Epitope {#s0075}
------------------------------------------------------------

To confirm the structural model of the ClfA/tefibazumab complex derived from the diffraction data we made several amino acid substitutions in the ClfA N3 domain at the tefibazumab epitope ([Fig. 3](#f0015){ref-type="fig"}A) and evaluated the effects of the substitutions on the overall ClfA-tefibazumab interaction. We found that changing Tyr512 in the F-strand of the N3 subdomain to Ala (Y512A) resulted in a slightly reduced binding to tefibazumab, while a triple mutant (ClfA~PWY~) comprising P467A, Y512A and W518A substitutions almost completely abolished tefibazumab binding to ClfA~221--559~ ([Fig. 3](#f0015){ref-type="fig"}B). Since all these three residues are surface exposed their substitutions should not cause gross structural changes to the protein. Circular dichroism spectroscopy (Fig. S2) indicates that ClfA~PWY~ is properly folded with a similar secondary structure composition as that of ClfA~221--559~.

3.6. The Tefibazumab/ClfA Complex Structure Implicates a Second Site Required for High Affinity Fibrinogen Binding to the MSCRAMM {#s0080}
---------------------------------------------------------------------------------------------------------------------------------

Superposition of the ClfA~CC~/Fg γ-peptide ligand complex and the ClfA/tefibazumab Fab inhibitor complex is shown in [Fig. 3](#f0015){ref-type="fig"}D. The peptide binding site is located between the N2 and the N3 subdomains and extends along the "G" strand of N3 while the tefibazumab epitope is found on "top" of N3 ([Fig. 3](#f0015){ref-type="fig"}D and E) and does not overlap with the peptide binding site. Thus we are left with an apparent paradox where tefibazumab effectively inhibits the ClfA/Fg interaction but the Fg γ-peptide binding site and the tefibazumab epitope do not overlap. Is it possible that the interaction of ClfA with Fg extends beyond the C-terminal section of the Fg γ-chain and that ClfA makes additional contacts with Fg? In support of a more complex Fg/ClfA binding mechanism we have found that a synthetic Fg γ-peptide, even at high concentrations, can only reduce Fg binding to the MSCRAMM by a maximum of \~ 50% ([@bb0055]). Tefibazumab may inhibit ClfA binding to Fg by blocking a potential second binding site. Four additional pieces of evidence support a binding model with at least two contact sites between Fg and ClfA.

### 3.6.1. Molecular Modeling of ClfA/Fg D-fragment {#s0085}

The possibility of multiple contacts between ClfA and Fg was first evaluated by molecular modeling studies. As tefibazumab inhibits ClfA binding to both Fg and the D-fragment in an almost identical way (Fig. S1C), and the affinity of ClfA for Fg and the D-fragment are very similar ([Fig. 4](#f0020){ref-type="fig"}C), it is likely that all the contacts between ClfA and Fg involve only the D-fragment. We therefore used the crystal structures of the Fg D-fragment (Pdb id: [2H43](pdb:2H43){#ir0025} ([@bb0025])) and ClfA~CC~ ([@bb0050]) for the modeling studies. The 17-residue C-terminal segment of the Fg γ-chain, which binds to ClfA in the N2N3 trench, corresponds to a disordered region and cannot be detected in the crystal structure of the \~ 80 kDa Fg D-fragment. Rigid body docking of the Fg D-fragment on ClfA~CC~ resulted in a model of the ClfA/D-fragment complex where the orientation of the C-terminal residue (His400) of the Fg γ-chain in the D-fragment structure is placed close to the N-terminal residue (Leu392) of the Fg γ-peptide in the ClfA/peptide structure. Molecular modeling showed that the docking of the C-terminal of the Fg γ-chain in the trench between the N2 and N3 subdomains could place the 30 kDa γ-globular module of the D-fragment close to the top face of the N3 domain of ClfA ([Fig. 3](#f0015){ref-type="fig"}F). In this model there is a substantial contact area between the D-fragment and the N3 domain of ClfA. Thus it is clear from the model that a second binding site located on "top" of the N3 domain of ClfA is sterically possible when the Fg γ-peptide is docked in the N2N3 trench.

### 3.6.2. Recombinant ClfA Domains Bind to Intact Fg or the Fg D-fragment With Significantly Higher Affinities Than to the Fg γ-peptide {#s0090}

A binding mechanism involving multiple contact sites in Fg with ClfA should result in a significant higher affinity of the MSCRAMM for full-length Fg compared to the Fg γ-peptide. An ITC experiment where ClfA~CC~ was titrated into a cell containing full-length Fg gave a *K*~D~ of 0.3 μM ([Fig. 4](#f0020){ref-type="fig"}A) whereas titrating a synthetic C-terminal γ-chain peptide into a cell containing ClfA~CC~ gave a *K*~D~ of 6.2 μM ([Fig. 4](#f0020){ref-type="fig"}B). The 20-fold higher affinity observed for full-length Fg is consistent with a model involving additional contacts between ClfA N2N3 and intact Fg beyond the Fg γ-peptide region and that these second site interactions contribute to the overall higher affinity.

SPR experiments where ClfA~229--545~ was run over chips containing immobilized intact Fg, Fg D-fragment or GST-γ showed about a 50-fold difference in *K*~D~ for binding of the MSCRAMM to the Fg γ-peptide and the Fg or Fg D-fragment, respectively ([Fig. 4](#f0020){ref-type="fig"}C, Supplementary Table ST5). On the other hand, the *K*~D~ values for ClfA binding to intact Fg or Fg D-fragment are very similar; 0.56 μM for Fg compared to 0.75 μM for the Fg D-fragment ([Fig. 4](#f0020){ref-type="fig"}C). Since most of the known and putative Fg interactive sites in ClfA are located within the N3 subdomain we examined the interactions of a recombinant form of N3 (ClfA~370--559~) to the different forms of immobilized Fg. ClfA N3 bound to all forms of Fg ([Fig. 4](#f0020){ref-type="fig"}D, Supplementary Table ST5). The *K*~D~ values for ClfA N3 binding to Fg or the Fg D-fragment were similar and about 10 fold higher than the *K*~D~ values measured for ClfA~229--545~ binding to the same proteins. The Fg γ-peptide bound to ClfA N3 with about 10-fold lower affinity than those for intact Fg or the Fg D-fragment. Taken together the results of these binding studies are consistent with our model proposing a second Fg binding site in ClfA and further suggest that all sites in Fg targeting the MSCRAMM are located in the D-fragment.

### 3.6.3. Amino Acid Substitutions in the Tefibazumab Epitope in ClfA Affect Fg but not Fg γ-peptide Binding to the MSCRAMM {#s0095}

We propose that tefibazumab inhibits the binding of ClfA to Fg by competing for the second Fg binding site on the MSCRAMM. If this model is correct, substitution of residues in the tefibazumab epitope may affect Fg binding to ClfA. Consequently, we examined the Fg binding of ClfA proteins (ClfA~Y512A~ and ClfA~PWY~) that were affected in mAb binding ([Fig. 3](#f0015){ref-type="fig"}A). SPR analysis using immobilized human Fg showed that the ClfA~Y512A~ exhibited reduced binding to Fg ([Fig. 3](#f0015){ref-type="fig"}B). The effect of the Y512A substitution was much more pronounced when Fg rather than tefibazumab was the ligand indicating that Tyr512 plays a more important role for Fg binding than for mAb binding. The triple mutant ClfA~PWY~ completely lost its ability to bind tefibazumab and showed minimal binding to Fg ([Fig. 3](#f0015){ref-type="fig"}B).

Furthermore our binding model predicts that substitution of the residues located on top of the N3 domain would not affect the binding of ClfA to the Fg γ-peptide. We used ITC to explore if the ClfA~PWY~ mutant has retained the ability to bind the Fg γ-peptide P16 ([Fig. 3](#f0015){ref-type="fig"}C). P16 is a 17 amino acid long Fg γ-peptide that contains one residue substitution (Asp to Ala at the 16th position of the γ-peptide) and binds ClfA with a higher affinity compared to a corresponding peptide with a wild type sequence ([@bb0050]). P16 bound ClfA~PWY~ with a similar affinity (*K*~D~ = 5.8 μM) to that previously recorded for P16 binding to ClfA~221--545~ (*K*~D~ = 3.0 μM) ([@bb0050]). In addition, SPR analysis of ClfA~PWY~ binding to Fg and the D-fragment, respectively, indicated K~D~ values in the low micromolar range (10 μM and 17 μM, respectively, data not shown) comparable to the Fg γ-peptide binding to ClfA (4.3 μM, [Fig. 3](#f0015){ref-type="fig"}F). These results suggest that the Dock, Lock and Latch mechanism of Fg binding remains intact in the ClfA~PWY~ mutant and that ClfA~PWY~ specifically lost the second Fg binding site.

### 3.6.4. Tefibazumab Does Not Inhibit the Fg γ-peptide binding to ClfA {#s8095}

If tefibazumab affect Fg binding only at the second site, but not in the N2N3 trench, we would not expect binding of the Fg γ-peptide to ClfA to be inhibited by the mAb. To evaluate this hypothesis, we used SPR analysis of tefibazumab-mediated inhibition of ClfA~221--545~ binding to immobilized GST-tagged Fg γ-peptide (GST-γ). ClfA~221--545~ could still bind to GST-γ in the presence of tefibazumab ([Fig. 5](#f0025){ref-type="fig"}). In fact the response is higher in the presence of the mAb, which likely reflects that a tefibazumab: ClfA~221--545~ complex is formed and bind to the immobilized GST-γ. To demonstrate that ClfA can simultaneously bind to the Fg γ-peptide and the mAb we took advantage of the relatively stable interaction between ClfA~CC~ and GST-γ, shown by a slower dissociation phase in the SPR curve ([Fig. 5](#f0025){ref-type="fig"}B). In this system the GST-γ bound ClfA~CC~ was still able to bind tefibazumab. Thus tefibazumab did not inhibit ClfA binding to GST-γ, while the mAb could inhibit ClfA~221--545~ binding to Fg (about 70%, [Fig. 1](#f0005){ref-type="fig"}D&E) and D-fragment (about 80%, Fig. S1C).

Taken together these results demonstrate that tefibazumab inhibits Fg binding by blocking a second binding site located at the top of the N3 domain which is distinct from the Fg γ-peptide binding site located in the trench between the N2N3 subdomains. A schematic diagram representing the regions of Fg and tefibazumab binding to ClfA and the mechanism of tefibazumab\'s partial inhibition of Fg binding to the MSCRAMM is shown in [Fig. 7](#f0035){ref-type="fig"}.

4. Discussion {#s0100}
=============

The crystal structure of ClfA N2N3 in complex with the Fab fragment generated from tefibazumab defines the epitope for this inhibiting mAb, which to our surprise is located on top of the N3 subdomain. Through biochemical studies we demonstrate that the tefibazumab epitope partially overlaps with a second Fg binding site, which is required for high affinity binding of Fg to ClfA. A substantial variation in the amino acid sequence of the identified tefibazumab epitope is apparent from examining ClfA sequences available in the public domain (Supplementary Table ST2). To evaluate the significance of these variations we expressed four of the more common tefibazumab epitope isoforms and determined their relative binding to immobilized tefibazumab by SPR. One of these isoforms (ClfA~N463R~) where Asn is replaced by the bulky charged residue Arg, showed a 60-fold reduced affinity for the mAb (*K*~D~ = 0.7 nM (ClfA~229--545~) to *K*~D~ = 45 nM (ClfA~N463R~) ([Fig. 6](#f0030){ref-type="fig"}A). Interestingly, this variant appears to have maintained its high affinity for Fg ([Fig. 6](#f0030){ref-type="fig"}B). These results demonstrate that tefibazumab recognizes some but not all naturally occurring ClfA variants of *S. aureus*. In addition, tefibazumab cannot completely block Fg binding to ClfA and although the recorded *K*~D~ for the mAb\'s binding to ClfA is low it is not quite as low as that demonstrated for the corresponding mouse mAb before being "humanized" ([Fig. 1](#f0005){ref-type="fig"}). Furthermore, the observed IC~50~ is rather high ([Fig. 1](#f0005){ref-type="fig"}), which may be a consequence of the complex Fg binding mechanism employed by ClfA. Taken together these properties may explain the modest effect of tefibazumab as an anti-staphylococcal therapy in humans ([@bb0205]).

Our earlier study showed that ClfA binding to Fg involves a variant of the Dock, Lock and Latch mechanism where the C-terminus of the Fg γ-chain docks in a trench formed between the N2 and N3 subdomains of the MSCRAMM ([@bb0050]). In the current report we demonstrate that the high affinity interaction of ClfA with intact Fg involves additional contacts between the MSCRAMM and the ligand protein. These additional interactions increase the overall affinity of the interaction and appear to involve residues in the γ-globular domain of the γ-chain of Fg that can be brought into close contact and interact with the "top" of the N3 domain according to our modeling experiments.

Is it possible that this complex, multi-contact binding mechanism here shown for the ClfA/Fg interaction, also applies to other ligand/MSCRAMM interactions. The Fg binding MSCRAMMs FnBPA ([@bb0200]), FnBPB ([@bb0015]) of *S. aureus* and Fbl of *S. lugdunensis* ([@bb0055]) all target the C-terminus of the Fg γ-chain using N2N3 segments with similar subdomain organization to ClfA. Thus Fg binding to these MSCRAMMs could also involve additional binding sites. A synthetic peptide corresponding to the linear sequence in Fg targeted by the related protein ClfB binds to the MSCRAMM with rather low affinity and the peptide is a poor inhibitor of Fg binding to ClfB (unpublished data). To account for the much higher affinity seen with intact Fg, ClfB like ClfA, may provide additional interactive sites outside the N2N3 trench. The Fg-binding MSCRAMM SdrG binds to a 15 amino acid linear Fg sequence in a rather high affinity interaction ([@bb0170]). In this case it is possible that additional sites are not required for an overall high affinity, although preliminary modeling experiments suggest that additional contacts are possible. Thus, although the DLL binding mechanism seems to be involved in most MSCRAMM ligand interactions additional contacts may be required for high affinity interactions. Furthermore, it is possible that sequence variations in the MSCRAMM at the second binding site could affect the affinity for Fg and thus the virulence potential of the ClfA variant. It is also possible that amino acid variations in human Fg sequences targeting the second site may bind with different affinities to the MSCRAMM and consequently affect the susceptibility of an individual to staphylococcal infections.

It should be pointed out that the study reported here has been conducted with a segment of ClfA and it is unclear if Fg binding to the full-length MSCRAMM can involve even more extensive interactions outside the N2N3 sub-domains. Our studies with tefibazumab have also revealed a novel inhibitory mechanism for the binding of ClfA to Fg. It is clear that the mechanism by which ClfA binds Fg is much more complex than previously appreciated and this complexity can at least partly explain the difficulty in generating effective anti-ClfA therapeutic agents including mAbs that can efficiently recognize natural ClfA variants from different strains of *S. aureus*. However, further characterization of the second binding site(s) may provide the opportunity to design antibodies and other molecules that interfere with both Fg-binding sites on ClfA to effectively inhibit this interaction that appears to be critical for *S. aureus* virulence ([@bb0100]).
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![SPR analysis of the ligand interactions and inhibitions. (**A**) Two-fold serial dilution of ClfA~229--545~ (from 32 to 1 nM) were injected to a tefibazumab surface (\~ 150 RU captured by goat anti-human IgG (Fc) polyclonal F(ab')~2~). SPR sensorgrams shown in black were fitted to a 1:1 Langmuir binding model curves shown in red. The derived dissociation constant *K*~D~ (0.81 nM) was calculated from the rate constants (*k*~a~ = 5.94 × 10^5^ M^− 1^ s^− 1^ and *k*~d~ = 4.90 × 10^− 4^ s^− 1^). (**B**) ClfA~229--545~ (from 1.28 to 0.04 μM) was injected to a Fg surface (10,000 RU on CM5 chip). The average responses at steady state (shown in red) were plotted as a function of the ClfA~229--545~ concentration and fit to a one-site binding (hyperbola) model (inset). *K*~D~ of 0.66 μM was determined. (**C** & **D**) Dose response for the inhibition of different concentrations (from 0.125 to 4 μM) of tefibazumab (C) or Fg (D) on 1 μM of ClfA~229--545~ binding to immobilized Fg. The maximum 100% response is ClfA~229--545~ binding without any inhibitors and shown as dashed lines. (**E**) Inhibition data from C&D were plotted against inhibitor concentrations (the monomer Fg concentration was used) and fitted to a four-parameter logistic function. The control is for the binding response without any inhibitor. The tefibazumab IC~50~ measured for inhibiting ClfA~229--545~ binding to Fg is 0.39 μM and the fitted minimum is 27%, the Fg IC~50~ is 0.48 μM and the fitted minimum is 0%. The binding of the inhibitors (at the highest concentration of 4 μM) to the Fg surface were very small (\< 10 RU), compared to the ClfA response of \~ 550 RU, so they were not subtracted from the total responses.](gr1){#f0005}

![ClfA-tefibazumab interactions. (**A**) The structure of disulfide bond-closed ClfA~CC~ in complex with the Fab fragment of tefibazumab. ClfA~CC~ N2 and N3 domains are shown in green and yellow, respectively. The light and the heavy chains of the Fab fragment are shown in magenta and cyan, respectively. (**B**) Hydrogen bonding and key interactions between ClfA and the light chain of tefibazumab. Hydrogen bonds are shown as dashed lines. ClfA residues are shown in yellow and light chain residues are shown in magenta. (**C**) Hydrogen bonding and key interactions between ClfA and the heavy chain of tefibazumab. Hydrogen bonds are shown as dotted lines. ClfA residues are shown in yellow and heavy chain residues are shown in cyan.](gr2){#f0010}

![Analysis of ClfA N3 site interactions with tefibazumab and fibrinogen. (**A**) Ribbon diagram of ClfA N3 domain showing alanine substitutions at the positions of P467, Y512 and W518 in blue. The Fg γ-peptide is shown as a red ribbon. (**B**) Biacore sensorgrams showing 0.1 μM of ClfA~221--559~ wt or variants run over immobilized tefibazumab and fibrinogen. The variant proteins used are indicated in panel A. (**C**) ClfA~PWY~ and Fg-γ P16 synthetic peptide interaction measured by ITC. Thermodynamic parameters values (*K*~D~ = 5.8 μM, ΔH = − 6.79 kcal/mol, ΔS = 1.6 cal/mol/K) are derived from this experiments. (**D**) Overlay of crystal structures of ClfA~CC~/Fg γ-peptide and the ClfA~CC~/tefibazumab Fab complex. The N2 and the N3 subdomains of ClfA and Fab complex are shown in green and yellow respectively and ClfA from the Fg γ-peptide complex (PDB: [2VR3](pdb:2VR3){#ir0005}) is shown in grey. Tefibazumab light and heavy chains are shown in magenta and cyan, respectively, and the Fg γ-peptide bound in the N2N3 trench is shown as a red ribbon. Note that the N2N3 site and the mAb epitope do not overlap. (**E**) Molecular surface representation of ClfA shown in green (N2 domain), yellow (N3 domain). The surface that contacts Fg γ-peptide and the light chain and heavy chains of tefibazumab are shown in red, gold and grey, respectively. (**F**) Molecular model of ClfA/Fg D-fragment interaction. ClfA N2 and N3 domains are colored green and yellow, respectively. The α, β, and γ chains of Fg D-fragment are shown in orange, light blue and red, respectively.](gr3){#f0015}

![Comparison of ClfA-Fg interactions. (**A** & **B**) Analysis of the interaction using ITC. Fg was placed in the cell and ClfA~CC~ was titrated in A, whereas ClfA~CC~ was placed in the cell and P16 was titrated in B. (**C**) SPR measurement of the interactions between ClfA~229--545~ and Fg molecules. Two-fold dilution of ClfA~229--545~ (1.28 to 0.04 μM, 8.0 to 0.125 μM, and 32 to 1 μM) were injected to Fg (600 RU), D-fragment (700 RU) and GST-γ (1500 RU) respectively. (**D**) SPR measurement of the interactions between ClfA N3 and Fg molecules. Two-fold dilution of ClfA N3 (12.8 to 0.1 or 0.4 μM) were injected to Fg (1000 RU), D-fragment (1000 RU) and GST-γ (2500 RU) respectively. SPR sensorgrams for binding at different concentration of proteins are shown as black lines. The average responses at steady state (shown in red) were used to generate a binding curve (inset) and the equilibrium dissociation constant *K*~D~ was determined.](gr4){#f0020}

![Effect of tefibazumab on ClfA binding to immobilized GST-γ. (**A**) SPR experiments for 5 μM ClfA~229--545~ binding to GST-γ surface (700 RU, captured by anti-GST pAb), in the presence (dashed line, with the tefibazumab background response subtracted) or absence (solid line) of 2 μM tefibazumab. (**B**) Taking advantage of the slow off-rate of ClfA~CC~ (5 μM) binding to GST-γ (black line), strong binding of 2 μM of tefibazumab to the GST-γ bound ClfA~CC~ was shown (in green), compared to non-specific binding of tefibazumab (2 μM, in blue) to the GST-γ.](gr5){#f0025}

![ClfA~229--545~ and some natural variants binding to tefibazumab and Fg. (**A**) Sensorgrams generated by binding of each ClfA protein at 32 nM concentration to the surface of tefibazumab (\~ 200 RU captured through goat anti-human IgG (Fc) polyclonal F(ab')~2~). Dissociation constants *K*~D~ for each ClfA/tefibazumab interaction are listed, and sensorgrams with fitting are shown in Supplementary Figure S3. (**B**) Binding of 320 nM of each protein to the immobilized Fg (about 600 RU) are overlaid and the *K*~D~ for each of the ClfA/Fg interactions is listed. Standard errors for the *K*~D~ measurements from different experiments (n ≥ 2).](gr6){#f0030}

![Schematic representation of the binding and inhibition mechanism of Fg and tefibazumab respectively to ClfA. (**A**) Domain organization of fibrinogen and ClfA. The inter chain disulfide bonds linking the individual α, β, and γ chains and the dimeric Fg molecule are shown as black lines. The α, β, and γ chain regions corresponding to D-fragment are shown in orange, light blue and red respectively. The N2 and the N3 subdomains in ClfA are colored green and yellow respectively. (**B**) A schematic model showing the Fg binding regions on ClfA and the tefibazumab epitope. Tefibazumab can only partially inhibit Fg binding to ClfA by competing for the second Fg binding site on the MSCRAMM.](gr7){#f0035}

###### 

Crystallographic data measurement and refinement data.

Table 1

                                                      ClfA/Tefibazumab
  --------------------------------------------------- -------------------
  Cell dimensions                                     
   a, b, c (Å)                                        234.2, 84.4, 48.0
   β (°)                                              99.07
   Space group                                        C2
   Max resolution (Å)                                 2.4
   Reflections unique                                 36,373
   Completeness (%)                                   99.5 (99)
   R~merge~[a](#tf0005){ref-type="table-fn"}          0.09
   Number of molecules in the asymmetric unit         1
   Rfactor/R~free~[b](#tf0010){ref-type="table-fn"}   0.207/0.259
   Average B value (Å)                                66
   No of non-hydrogen atoms                           5551
   ClfA                                               2393
   Tefibazumab                                        2953
   Water                                              205
  Rms deviations from ideal values                    
   Bond lengths (Å)                                   0.010
   Bond Angles (°)                                    1.26

R~merge~ = Σ ∣ I~j~ − 〈I〉∣ / ΣI~i~; where I~j~ is the measured and 〈I〉 is the mean intensity of reflection hkl.

R~free~ is calculated over 5% of randomly selected reflections not included in the refinement.

[^1]: Shared first authors.
